101 related articles for article (PubMed ID: 18753414)
1. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
Maillard CM; Bouquet C; Petitjean MM; Mestdagt M; Frau E; Jost M; Masset AM; Opolon PH; Beermann F; Abitbol MM; Foidart JM; Perricaudet MJ; Noël AC
Carcinogenesis; 2008 Nov; 29(11):2236-42. PubMed ID: 18753414
[TBL] [Abstract][Full Text] [Related]
2. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
3. Fracture healing in mice deficient in plasminogen activator inhibitor-1.
Rundle CH; Wang X; Wergedal JE; Mohan S; Lau KH
Calcif Tissue Int; 2008 Oct; 83(4):276-84. PubMed ID: 18820962
[TBL] [Abstract][Full Text] [Related]
4. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Maillard C; Jost M; Rømer MU; Brunner N; Houard X; Lejeune A; Munaut C; Bajou K; Melen L; Dano K; Carmeliet P; Fusenig NE; Foidart JM; Noel A
Neoplasia; 2005 Jan; 7(1):57-66. PubMed ID: 15720817
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor).
Fen Li C; Kandel C; Baliko F; Nadesan P; Brünner N; Alman BA
Oncogene; 2005 Feb; 24(9):1615-24. PubMed ID: 15674349
[TBL] [Abstract][Full Text] [Related]
6. A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer.
Frau E; Magnon C; Opolon P; Connault E; Opolon D; Beermann F; Abitbol M; Perricaudet M; Bouquet C
Cancer Gene Ther; 2007 Mar; 14(3):251-61. PubMed ID: 17082795
[TBL] [Abstract][Full Text] [Related]
7. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
[TBL] [Abstract][Full Text] [Related]
8. Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.
Sato Y; Dong J; Imagawa S; Ishimori N; Furumoto T; Tsutsui H; Sobel BE; Fujii S
Coron Artery Dis; 2008 Aug; 19(5):355-61. PubMed ID: 18607173
[TBL] [Abstract][Full Text] [Related]
9. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Bugge TH; Lund LR; Kombrinck KK; Nielsen BS; Holmbäck K; Drew AF; Flick MJ; Witte DP; Danø K; Degen JL
Oncogene; 1998 Jun; 16(24):3097-104. PubMed ID: 9671388
[TBL] [Abstract][Full Text] [Related]
10. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.
Lademann U; Rømer MU; Jensen PB; Hofland KF; Larsen L; Christensen IJ; Brünner N
Eur J Cancer; 2005 May; 41(7):1095-100. PubMed ID: 15862760
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury.
Abderrahmani R; François A; Buard V; Benderitter M; Sabourin JC; Crandall DL; Milliat F
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):942-8. PubMed ID: 19480973
[TBL] [Abstract][Full Text] [Related]
13. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Rømer MU; Kirkebjerg Due A; Knud Larsen J; Hofland KF; Christensen IJ; Buhl-Jensen P; Almholt K; Lerberg Nielsen O; Brünner N; Lademann U
Thromb Haemost; 2005 Oct; 94(4):859-66. PubMed ID: 16270643
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells.
Tsuchiya H; Sunayama C; Okada G; Matsuda E; Tomita K; Binder BR
Anticancer Res; 1997; 17(1A):313-6. PubMed ID: 9066670
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice.
Chijiwa T; Abe Y; Ikoma N; Yamazaki H; Tsukamoto H; Suemizu H; Kawai K; Wakui M; Nishime C; Matsumoto H; Matsuyama M; Mukai M; Ueyama Y; Nakamura M
Int J Oncol; 2009 Jan; 34(1):5-13. PubMed ID: 19082472
[TBL] [Abstract][Full Text] [Related]
16. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition.
Copland IB; Lord-Dufour S; Cuerquis J; Coutu DL; Annabi B; Wang E; Galipeau J
Stem Cells; 2009 Feb; 27(2):467-77. PubMed ID: 19338064
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice.
Grant MB; Spoerri PE; Player DW; Bush DM; Ellis EA; Caballero S; Robison WG
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2296-302. PubMed ID: 10892876
[TBL] [Abstract][Full Text] [Related]
18. Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE.
Foletti A; Ackermann J; Schmidt A; Hummler E; Beermann F
Oncogene; 2002 Mar; 21(12):1841-7. PubMed ID: 11896616
[TBL] [Abstract][Full Text] [Related]
19. ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.
De la Houssaye G; Vieira V; Masson C; Beermann F; Dufier JL; Menasche M; Abitbol M
Mol Vis; 2008; 14():1912-28. PubMed ID: 18958307
[TBL] [Abstract][Full Text] [Related]
20. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
